Peripheral blood T-cell receptor repertoire as a predictor of clinical outcomes in gastrointestinal cancer patients treated with PD-1 inhibitor

医学 危险系数 T细胞受体 内科学 置信区间 剧目 肿瘤科 胃肠病学 队列 癌症 免疫学 免疫系统 T细胞 物理 声学
作者
Sunhee Ji,J. Li,L. Chang,Chuanhua Zhao,Ru Jia,Zhao-Li Tan,Ruihua Liu,Y Zhang,Y Li,G. Yin,Yanfang Guan,Xuefeng Xia,X. Yi,Jianming Xu
出处
期刊:Clinical & Translational Oncology [Springer Science+Business Media]
卷期号:23 (8): 1646-1656 被引量:26
标识
DOI:10.1007/s12094-021-02562-4
摘要

Identifying valid biomarkers for patient selection impressively promotes the success of anti-PD-1 therapy. However, the unmet need for biomarkers in gastrointestinal (GI) cancers remains significant. We aimed to explore the predictive value of the circulating T-cell receptor (TCR) repertoire for clinical outcomes in GI cancers who received anti-PD-1 therapy. 137 pre- and 79 post-treated peripheral blood samples were included. The TCR repertoire was evaluated by sequencing of complementarity-determining region 3 (CDR3) in the TRB gene. The Shannon index was used to measure the diversity of the TCR repertoire, and Morisita’s overlap index was used to determine TCR repertoire similarities between pre- and post-treated samples. Among all enrolled patients, 76 received anti-PD-1 monotherapy and 61 received anti-PD-1 combination therapy. In the anti-PD-1 monotherapy cohort, patients with higher baseline TCR diversity exhibited a significantly higher disease control rate (77.8% vs. 47.2%; hazard ratio [HR] 3.92; 95% confidence interval [CI] 1.14–13.48; P = 0.030) and a longer progression-free survival (PFS) (median: 6.47 months vs. 2.77 months; HR 2.10; 95% CI 1.16–3.79; P = 0.014) and overall survival (OS) (median: NA vs. 8.97 months; HR 3.53; 95% CI 1.49–8.38; P = 0.004) than those with lower diversity. Moreover, patients with a higher TCR repertoire similarity still showed a superior PFS (4.43 months vs. 1.84 months; HR 13.98; 95% CI 4.37–44.68; P < 0.001) and OS (13.40 months vs. 6.12 months; HR 2.93; 95% CI 1.22–7.03; P = 0.016) even in the cohort with lower baseline diversity. However, neither biomarker showed predictive value in the anti-PD-1 combination therapy cohort. Interestingly, the combination of TCR diversity and PD-L1 expression can facilitate patient stratification in a pooled cohort. The circulating TCR repertoire can serve as a predictor of clinical outcomes in anti-PD-1 therapy in GI cancers.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
情怀的应助被科研通管家采纳,获得10
刚刚
刚刚
搜集达人的应助被科研通管家采纳,获得10
刚刚
领导范儿的应助被天外来物采纳,获得10
刚刚
科研通AI2S的应助被科研通管家采纳,获得10
刚刚
充电宝的应助被科研通管家采纳,获得10
刚刚
1097发布了新的文献求助10
刚刚
aajhajkahna的应助被科研通管家采纳,获得10
刚刚
汉堡包的应助被科研通管家采纳,获得10
1秒前
深情安青的应助被科研通管家采纳,获得10
1秒前
1秒前
Owen的应助被科研通管家采纳,获得10
1秒前
心香驳回了MM的应助
1秒前
小马甲的应助被科研通管家采纳,获得10
1秒前
急急急发布了新的文献求助10
1秒前
molihuakai的应助被科研通管家采纳,获得10
1秒前
英俊的铭的应助被科研通管家采纳,获得10
1秒前
1秒前
n11发布了新的文献求助10
1秒前
Owen的应助被科研通管家采纳,获得10
1秒前
vnewgnl的应助被科研通管家采纳,获得20
2秒前
2秒前
星1993发布了新的文献求助10
2秒前
2秒前
春申君发布了新的文献求助10
2秒前
紧张的谷槐完成签到,获得积分10
2秒前
上官若男的应助被科研通管家采纳,获得10
2秒前
Hello的应助被科研通管家采纳,获得10
2秒前
小蘑菇的应助被科研通管家采纳,获得10
2秒前
orixero的应助被科研通管家采纳,获得10
2秒前
CipherSage的应助被鱿鱼的云朵采纳,获得10
2秒前
天天快乐的应助被科研通管家采纳,获得10
3秒前
鲁万仇发布了新的文献求助10
3秒前
syvshc的应助被科研通管家采纳,获得10
3秒前
田様的应助被科研通管家采纳,获得10
3秒前
852的应助被科研通管家采纳,获得10
3秒前
思源的应助被科研通管家采纳,获得10
3秒前
星辰大海的应助被科研通管家采纳,获得10
3秒前
爆米花的应助被科研通管家采纳,获得10
3秒前
小蘑菇的应助被科研通管家采纳,获得10
3秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183142
求助须知:如何正确求助?哪些是违规求助? 9572420
关于积分的说明 21825253
捐赠科研通 7779922
什么是DOI,文献DOI怎么找? 3433850
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480124